eXmoor and Signadori Bio enter cell therapy partnership

Signadori is advancing a platform designed to overcome the challenges of treating solid cancers

eXmoor Pharma and Signadori Bio have entered into a partnership aimed at advancing a gene-modified monocyte-derived macrophage cell therapy programme for solid tumours.

The collaboration agreement will see eXmoor, an integrated cell and gene therapy contract development and manufacturing organisation, support Signadori in the transition from discovery through to good manufacturing practice (GMP)-compliant manufacturing of its lead candidate.

eXmoor will carry out a technology translation and…